MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

10 of the Most Influential Companies in the Cardiovascular Space

The cardiovascular space has been among the most exciting in medtech in recent years. MD+DI has compiled a list of companies in the market that are having a profound impact.

  • 10 of the Most Influential Companies in the Cardiovascular Space

    The cardiovascular space has been among the most exciting in medtech in recent years.  MD+DI has compiled a list of 10 companies in the space that have had a profound impact in the cardiology market.

    Data on market capitalization, 2018 revenue, and position were derived from MD+DI's database of 115 Medtech Companies of 2018. Sources for the database are FactSet, Bloomberg LP, and company filings.

  • Abiomed
    Market Capitalization: $15B
    2018 Revenue: $690M
    Rank in Database: 79
    Current controversy non-withstanding, Abiomed has been a focal point for innovation in the cardiology market. The Danvers, MA-based company markets and produces the Impella technology, a family of medical devices used for temporary ventricular support device in people with depressed heart function. Impella’s tag line is the world’s smallest heart pump. Abiomed gained access to the technology when it acquired Impella CardioSystems AG in 2005.

  • LivaNova
    Market Capitalization:
    $4.5 billion
    2018 Revenue: $1.1 billion
    Rank in Database: 59
    Ever hear two of your favorite artists and thought what it would be like if they did a duet? Well LivaNova answered that question in the cardiology – in a way. In 2015, Sorin and Cyberonics took part in a merger valued at $2.7 billion and the result was LivaNova. The London-based company has recently been involved in clinical trials to help it gain a more dominant position in the transcatheter mitral valve replacement market. The firm made a significant move to pump up its cardiac surgery portfolio when it said it would pay up to $250 million to acquire TandemLife.

  • Integer Holdings Corp.
    Market Capitalization: $2.5B
    2018 Revenue: $1.3B
    Rank in Database: 53
    Sometimes it’s all about focusing on your passion and what works for you. And that’s exactly what Integer did a year ago, when it divested its Advanced Surgical and Orthopedics unit. The Frisco, TX-based company enacted this measure to turn its attention to its Cardio & Vascular and Cardiac & Neuromodulation offerings. Integer is the result of GreatBatch and Lake Region Medical merging in 2015.

  • Teleflex
    Market Capitalization:
    2018 Revenue: $2.4B
    Rank in Database: 37
    Teleflex like some other companies on the list has a broad array of offerings outside of the cardiovascular realm. What helps the Wayne, PA-based company stay in the spotlight for this list however, is its renewed focus on structural heart market. The company acquired Essential Medical in October of 2018 and gained access to the Manta Vascular Closure System. The device is a solution to address closure-related complications and high costs associated with many large and rapidly growing interventional procedure categories, such as transcatheter aortic valve replacement, endovascular aneurysm repair and ventricular assist device implantation.

  • Edwards Lifesciences
    Market Capitalization:
    2018 Revenue: $3.6B
    Rank in Database: 22
    Two things go hand-in-hand. Edwards Lifesciences and transcatheter aortic valve replacement (TAVR) procedures. The Irvine, CA-based company is known as the pioneer in TAVR being the first to have an approval for the devices in both the U.S. and Europe. Recently the company gained FDA approval for the long-awaited Sapien 3 Ultra. The valve features a heightened outer skirt designed to eliminate paravalvular leak. The new delivery system introduces an "on balloon" design, removing the need for valve alignment during the procedure.

  • Boston Scientific
    Market Capitalization: $9.8B
    2018 Revenue: $49B
    Rank in Database: 13
    Boston Scientific has its hands in many markets. But there are two devices that really helped put the Marlborough, MA-based company on the list. The first was the Watchman Left Atrial Appendage Closure Device an implant used to block the left atrial appendage of the heart, a common area for blood clot formations in patients with atrial fibrillation. The Watchman was a game-changer for the company and helped drive sales for Boston Scientific’s structural heart unit. The other device that is helping to transform Boston Scientific is its Lotus TAVR device. The company recently gained FDA approval for the Lotus Edge. The device’s approval helped end the duopoly Medtronic and Edwards had on the TAVR market.

  • Cardinal Health
    Market Capitalization: $13.3B
    2018 Revenue: $15.7B
    Rank in Database: 8
    Johnson & Johnson’s divestiture of Cordis was Cardinal Health’s gain. For years Cordis was known as the company that helped first bring drug-eluting stents (DES) to the market. Cardinal Health  picked up the Cordis unit for $2 billion in 2015. In recent years, Cardinal Health has stumbled a bit with Cordis citing it did not have clear “visibility” into the Cordis' inventory. This visibility created issues in Cardinal Health’s manufacturing operations.

  • Abbott Laboratories
    Market Capitalization: $127B
    2018 Revenue: $17B
    Rank in Database: 5
    Abbott Laboratories was powerful enough in its own right in cardiology. But then you add St. Jude Medical to the mix? Game Over! Now Abbott has devices like the Amplatzer PFO Occluder; the Assurity and Endurity MRI Pacemakers, and CardioMems Heart Failure system. The $25 billion merger between the two helped reinvigorate and change the landscape for cardiology.


  • Johnson & Johnson
    Market Capitalization: $346B
    2018 Revenue: $27B
    Rank in Database: 2
    Johnson & Johnson perhaps has the highest valuation and revenue out of all of the other firms on the list - a true giant in the industry. Not simply focused on devices, the company has an extremely high yield in pharma. Recently, J&J began gradually shrinking its medtech division to focus on more profitable sectors like pharmaceuticals. But its influence in the cardiology space can’t be ignored or disputed. From its former Cordis unit, that helped usher in drug-eluting stents, to its Biosense Webster business that recently launched a study to evaluate a radiofrequency balloon ablation catheter for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation, J&J has made an impact.

  • Medtronic
    Market Capitalization:
    2018 Revenue: $30.3B
    Rank in Database: 1
    Medtronic’s merger with Covidien not only transformed the cardiology market, but it completely redefined mega-mergers in medtech. The Dublin-based company became the big dog on the block. Combine that with Covidien's offerings in mHealth, stents, and plaque removal systems and you've got a checkmate in the industry. Since the merger, Medtronic has made other acquisitions including one that netted it HeartWare, which gave it a front row seat into the Left Ventricular Device space.  Checkmate indeed. 

Filed Under
500 characters remaining